2024
1378P Improvements in stage IV non-small cell lung cancer survival differ by race in the US
Ayoade O, Canavan M, Kim S, Boffa D. 1378P Improvements in stage IV non-small cell lung cancer survival differ by race in the US. Annals Of Oncology 2024, 35: s865. DOI: 10.1016/j.annonc.2024.08.1433.Peer-Reviewed Original ResearchQuantifying the Association between Pump Use and Breastfeeding Duration
Nardella D, Canavan M, Sharifi M, Taylor S. Quantifying the Association between Pump Use and Breastfeeding Duration. The Journal Of Pediatrics 2024, 274: 114192. PMID: 39004167, DOI: 10.1016/j.jpeds.2024.114192.Peer-Reviewed Original ResearchNon-Hispanic blacksBreastfeeding durationBreastfeeding cessationPump usePregnancy Risk Assessment Monitoring System dataAssociated with longer breastfeeding durationNon-Hispanic whitesMagnitude of associationAssociated with breastfeeding durationLonger breastfeeding durationCox proportional hazards regressionCross-sectional analysisProportional hazards regressionNative American participantsBreastfeeding inequitiesBreastfeeding outcomesInitiate breastfeedingLive-born infantsNon-missing dataUnmarried statusSurvey completionMonitoring system dataLow-incomeStratified analysisHazards regressionSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioPrognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma
Shimer S, Allen O, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith C, Adelson K. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal Of Palliative Medicine 2024, 27: 879-887. PMID: 38990245, DOI: 10.1089/jpm.2023.0530.Peer-Reviewed Original ResearchGoals of carePrognostic awarenessQuality of lifeIllness understandingPrognostic understandingMultiple myelomaHematologic malignanciesAcute leukemiaFaith-based responseInformed treatment choicesChi-square testCohort of patientsLikelihood ratio chi-square testMount Sinai HospitalTreatment goalsMM cohortSinai HospitalCarePatient populationTreatment choiceHospitalized patientsHematologistsAssess discordanceLeukemiaPatientsSurgical and Endoscopic Management of Clinical T1b Esophageal Cancer
Ayoade O, Canavan M, De Santis W, Zhan P, Boffa D. Surgical and Endoscopic Management of Clinical T1b Esophageal Cancer. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 38925509, DOI: 10.1016/j.jtcvs.2024.06.011.Peer-Reviewed Original ResearchEsophageal cancerTumor attributesEsophagectomy patientsEndoscopic treatmentAccelerated time failure modelsEndoscopic managementTumor size > 1 cmFactors associated with upstagingOccult lymph node metastasisAssociated with improved survivalAssociated with lymphovascular invasionEffect of esophagectomyT1b esophageal cancerTreatment naive patientsNational Cancer DatabaseWell-differentiated tumorsKaplan Meier analysisLymph node metastasisPoor tumor differentiationTime failure modelsNodal upstagingLymphovascular invasionOverall survivalEndoscopic patientsMeier analysisSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapyAssociation of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer
Maduka R, Canavan M, Walters S, Ermer T, Zhan P, Kaminski M, Li A, Pichert M, Salazar M, Prsic E, Boffa D. Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer. Cancer Medicine 2024, 13: e7028. PMID: 38711364, PMCID: PMC11074703, DOI: 10.1002/cam4.7028.Peer-Reviewed Original ResearchConceptsOptimal quality of careQuality of carePatient socioeconomic statusAssociated with improved qualityAssociated with improved quality of lifeEnd-of-lifeUS cancer populationPalliative treatmentQuality of lifeCox proportional hazards modelsMultivariate logistic regressionInformed decision makingProportional hazards modelFacility characteristicsNon-HispanicAssociated with lower ratesInsurance payer statusImproving informed decision makingCancer populationSocioeconomic statusHispanic ethnicityTreatment usePayer statusBlack raceLogistic regressionSources of Contraception Among Adolescents and Young Adults
Shankar M, Wood S, Sharifi M, Costa D, Canavan M, McNamara M, Camenga D. Sources of Contraception Among Adolescents and Young Adults. JAMA Pediatrics 2024, 178: 502-504. PMID: 38526498, PMCID: PMC10964153, DOI: 10.1001/jamapediatrics.2024.0111.Peer-Reviewed Original ResearchSalvage lung resection after immunotherapy is feasible and safe
Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D, Martin L, Yang C, Boffa D, Dhanasopon A. Salvage lung resection after immunotherapy is feasible and safe. JTCVS Open 2024, 20: 141-150. PMID: 39296459, PMCID: PMC11405986, DOI: 10.1016/j.xjon.2024.03.018.Peer-Reviewed Original ResearchNon-small cell lung cancerComplete pathologic responseSalvage lung resectionNational Cancer DatabaseLength of stayStages I-IVLung resectionOligo-progressionOverall survivalSalvage surgeryComplete resection (R0Comprehensive multidisciplinary treatment planHigher R0 resection rateCohort study of patientsInitiation of immunotherapyR0 resection rateTreated with immunotherapySalvage treatment optionMortality rateCell lung cancerLow patient morbidityMedian length of stayKaplan-Meier analysisMultidisciplinary treatment planStudy of patients
2023
Awareness of racial/ethnic inequities in time to treatment among breast cancer providers.
Cohen I, Canavan M, Jacob A, Sondhi A, Silver H, Bramwell L, Lustberg M, Adelson K. Awareness of racial/ethnic inequities in time to treatment among breast cancer providers. JCO Oncology Practice 2023, 19: 584-584. DOI: 10.1200/op.2023.19.11_suppl.584.Peer-Reviewed Original ResearchBreast cancer providersCancer providersRace/ethnicityEthnic inequitiesTreatment inequitiesExact testSmilow Cancer HospitalYale Cancer CenterHospital-level factorsEducational interventionAdverse social determinantsFisher's exact testDe-identified databaseBrief educational interventionNon-Latinx WhitesPatient factorsWhite patientsProvider factorsCancer HospitalCancer CenterCancer patientsOncological careCare metricsClinical armTreatment metricsRespect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy
Li A, Canavan M, Ermer T, Maduka R, Zhan P, Pichert M, Boffa D, Blasberg J. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. The Annals Of Thoracic Surgery 2023, 117: 163-171. PMID: 37774762, DOI: 10.1016/j.athoracsur.2023.09.023.Peer-Reviewed Original ResearchConceptsLower bilobectomyLeft pneumonectomyLung cancerMiddle lobeRight-sided lung cancerCox proportional hazards modelThirty-day morbidityTotal lung functionPreoperative risk stratificationThoracic Surgeons databaseProportional hazards modelPneumonectomy patientsUpper bilobectomyBronchial involvementPerioperative mortalityPerioperative riskPerioperative variablesPatient demographicsPulmonary resectionRight pneumonectomySecondary outcomesLung functionMiddle lobectomyPrimary outcomePropensity matchingAssessment of a collaborative treatment model for trimodal management of esophageal cancer
Udelsman B, Ermer T, Ely S, Canavan M, Zhan P, Boffa D, Blasberg J. Assessment of a collaborative treatment model for trimodal management of esophageal cancer. Journal Of Thoracic Disease 2023, 15: 4668-4680. PMID: 37868899, PMCID: PMC10586936, DOI: 10.21037/jtd-23-346.Peer-Reviewed Original ResearchPathologic complete responseNational Cancer DatabaseGy of radiationEsophageal cancerCollaborative treatmentCollaborative treatment modelMultiagent chemotherapySingle institutionRate of pCRPatient travel burdenR0 resection rateTreatment modelTrimodality therapyTrimodality treatmentNeoadjuvant chemoradiotherapyNeoadjuvant therapyR0 resectionResection rateComplete responseMultivariable analysisTumor characteristicsCancer DatabaseMedian travel distancePatientsCollaborative CohortAssessing changes in adolescent girls’ and young women’s sexual and reproductive health service utilisation following a COVID-19 lockdown in eSwatini
Brault M, Linnander E, Ginindza T, Mabuza K, Christie S, Canavan M, Jones A, Desai M. Assessing changes in adolescent girls’ and young women’s sexual and reproductive health service utilisation following a COVID-19 lockdown in eSwatini. Global Health Action 2023, 16: 2243760. PMID: 37565704, PMCID: PMC10424588, DOI: 10.1080/16549716.2023.2243760.Peer-Reviewed Original ResearchConceptsElectronic health record systemsYoung womenHealth service utilisationAdolescent girlsReproductive health service utilisationInterrupted time series analysisService utilisationHealth record systemsUtilisation dataMonthly visitsReproductive healthVisit trendsCOVID-19 lockdown periodRecord systemTwo-year periodCOVID-19 lockdownWomenSaharan AfricaSignificant changesCOVID-19 periodLockdown periodManzini regionGirlsEswatiniAGYWOverall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortalityEnd-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher oddsSurvival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns. Journal Of Clinical Oncology 2023, 41: 6562-6562. DOI: 10.1200/jco.2023.41.16_suppl.6562.Peer-Reviewed Original ResearchReal-world overall survivalSystemic anticancer therapySurvival analysisNon-small cell lungCox proportional hazards modelPractice-level factorsRenal cell carcinomaProportional hazards modelCommon cancer typesDe-identified databaseElectronic health recordsAdvanced diseaseAdult patientsHazard ratioMetastatic diseaseMost patientsOverall survivalSurvival benefitSystemic treatmentAggressive endPrimary outcomeCell carcinomaCell lungPrimary exposureCancer patientsThe association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM).
Canavan M, Sheth K, Scott J, Westvold S, Adelson K. The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: 6580-6580. DOI: 10.1200/jco.2023.41.16_suppl.6580.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useIntensive care unitInpatient admissionsED visitsCare useReceipt of chemotherapyAcute care utilizationEmergency department useProportion of decedentsRates of chemotherapyChi-square testICU stayIO therapyCare unitCare utilizationInpatient stayCT patientsDepartment useHospice useCare metricsOncology practiceThe impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM).
Adelson K, Canavan M, Sheth K, Scott J, Westvold S. The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: e18923-e18923. DOI: 10.1200/jco.2023.41.16_suppl.e18923.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useSystemic therapyCT patientsCare useImpact of receiptMean episode costReceipt of chemotherapyReceipt of immunotherapyICU useED costsIO patientsPharmacy costsOncology practiceEpisode costsTreatment decisionsDownstream careCare modelAmbulatory settingPart BPatientsImmunotherapyASO Visual Abstract: Association Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer—Potential for Stage Classification Reform
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Udelsman B, Nemeth A, Boffa D. ASO Visual Abstract: Association Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer—Potential for Stage Classification Reform. Annals Of Surgical Oncology 2023, 30: 4192-4192. DOI: 10.1245/s10434-023-13397-4.Peer-Reviewed Original ResearchAssociation Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Udelsman B, Nemeth A, Boffa D. Association Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform. Annals Of Surgical Oncology 2023, 30: 4180-4191. PMID: 36869917, DOI: 10.1245/s10434-023-13287-9.Peer-Reviewed Original ResearchConceptsStage IV gastric cancerNonregional lymph nodesMultivariable Cox modelLymph nodesGastric cancerMetastatic patternCox modelStage IV gastric cancer patientsBetter median survivalNational Cancer DatabaseRetrospective cohort studyStage IV patientsKaplan-Meier curvesGastric cancer patientsPropensity score-matched sampleSingle organYears of ageDistant diseaseCohort studyIV patientsMedian survivalMetastatic diseaseMost patientsBetter prognosisSystemic organs